319 related articles for article (PubMed ID: 34163469)
1. Diversity of Dominant Peripheral T Cell Receptor Clone and Soluble Immune Checkpoint Proteins Associated With Clinical Outcomes Following Immune Checkpoint Inhibitor Treatment in Advanced Cancers.
Li Y; Wang J; Wu L; Li X; Zhang X; Zhang G; Xu S; Sun S; Jiao S
Front Immunol; 2021; 12():649343. PubMed ID: 34163469
[TBL] [Abstract][Full Text] [Related]
2. Peripheral blood T-cell receptor repertoire as a predictor of clinical outcomes in gastrointestinal cancer patients treated with PD-1 inhibitor.
Ji S; Li J; Chang L; Zhao C; Jia R; Tan Z; Liu R; Zhang Y; Li Y; Yin G; Guan Y; Xia X; Yi X; Xu J
Clin Transl Oncol; 2021 Aug; 23(8):1646-1656. PubMed ID: 33583004
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of soluble B and T lymphocyte attenuator predict overall survival in patients undergoing immune checkpoint inhibitor therapy for solid malignancies.
Gorgulho J; Roderburg C; Heymann F; Schulze-Hagen M; Beier F; Vucur M; Kather JN; Laleh NG; Tacke F; Brümmendorf TH; Luedde T; Loosen SH
Int J Cancer; 2021 Sep; 149(5):1189-1198. PubMed ID: 33890289
[TBL] [Abstract][Full Text] [Related]
4. Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer.
Hurkmans DP; Basak EA; Schepers N; Oomen-De Hoop E; Van der Leest CH; El Bouazzaoui S; Bins S; Koolen SLW; Sleijfer S; Van der Veldt AAM; Debets R; Van Schaik RHN; Aerts JGJV; Mathijssen RHJ
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461348
[TBL] [Abstract][Full Text] [Related]
5. Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition.
Lyu Q; Lin A; Cao M; Xu A; Luo P; Zhang J
Cancer Control; 2020; 27(1):1073274820976665. PubMed ID: 33356494
[TBL] [Abstract][Full Text] [Related]
6. Soluble immune checkpoint molecules: Serum markers for cancer diagnosis and prognosis.
Chakrabarti R; Kapse B; Mukherjee G
Cancer Rep (Hoboken); 2019 Aug; 2(4):e1160. PubMed ID: 32721130
[TBL] [Abstract][Full Text] [Related]
7. Identification of immune checkpoint and cytokine signatures associated with the response to immune checkpoint blockade in gastrointestinal cancers.
Zhao C; Wu L; Liang D; Chen H; Ji S; Zhang G; Yang K; Hu Y; Mao B; Liu T; Yu Y; Zhang H; Xu J
Cancer Immunol Immunother; 2021 Sep; 70(9):2669-2679. PubMed ID: 33624146
[TBL] [Abstract][Full Text] [Related]
8. Genome and Transcriptome Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors.
Pender A; Titmuss E; Pleasance ED; Fan KY; Pearson H; Brown SD; Grisdale CJ; Topham JT; Shen Y; Bonakdar M; Taylor GA; Williamson LM; Mungall KL; Chuah E; Mungall AJ; Moore RA; Lavoie JM; Yip S; Lim H; Renouf DJ; Sun S; Holt RA; Jones SJM; Marra MA; Laskin J
Clin Cancer Res; 2021 Jan; 27(1):202-212. PubMed ID: 33020056
[TBL] [Abstract][Full Text] [Related]
9. Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.
Gjoerup O; Brown CA; Ross JS; Huang RSP; Schrock A; Creeden J; Fabrizio D; Tolba K
AAPS J; 2020 Oct; 22(6):132. PubMed ID: 33057937
[TBL] [Abstract][Full Text] [Related]
10. Peripheral Blood-Based Biomarkers for Immune Checkpoint Inhibitors.
An HJ; Chon HJ; Kim C
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502325
[TBL] [Abstract][Full Text] [Related]
11. Predictive Value of
Chen XJ; Ren AQ; Zheng L; Zheng ED
Front Immunol; 2021; 12():664847. PubMed ID: 33953726
[TBL] [Abstract][Full Text] [Related]
12. Editorial: Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer.
Dermime S; Merhi M; Merghoub T
Front Immunol; 2021; 12():781872. PubMed ID: 34745152
[No Abstract] [Full Text] [Related]
13. Peripheral T cell receptor repertoire features predict durable responses to anti-PD-1 inhibitor monotherapy in advanced renal cell carcinoma.
Kato T; Kiyotani K; Tomiyama E; Koh Y; Matsushita M; Hayashi Y; Nakano K; Ishizuya Y; Wang C; Hatano K; Kawashima A; Ujike T; Fujita K; Nonomura N; Uemura M
Oncoimmunology; 2021 Jan; 10(1):1862948. PubMed ID: 33537170
[TBL] [Abstract][Full Text] [Related]
14. Construction of an immune-related gene signature for prediction of prognosis in patients with cervical cancer.
Mei J; Xing Y; Lv J; Gu D; Pan J; Zhang Y; Liu J
Int Immunopharmacol; 2020 Nov; 88():106882. PubMed ID: 32799114
[TBL] [Abstract][Full Text] [Related]
15. Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer.
Sun D; Tian L; Zhu Y; Wo Y; Liu Q; Liu S; Li H; Hou H
Mol Med; 2020 Aug; 26(1):78. PubMed ID: 32791957
[TBL] [Abstract][Full Text] [Related]
16. Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities.
Xu Y; Fu Y; Zhu B; Wang J; Zhang B
Front Immunol; 2020; 11():2023. PubMed ID: 33123120
[TBL] [Abstract][Full Text] [Related]
17. Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma.
Jiang J; Ding Y; Wu M; Chen Y; Lyu X; Lu J; Wang H; Teng L
Cancer Med; 2020 Nov; 9(22):8498-8518. PubMed ID: 32969604
[TBL] [Abstract][Full Text] [Related]
18. CD8 lymphocytes in tumors and nonsynonymous mutational load correlate with prognosis of bladder cancer patients treated with immune checkpoint inhibitors.
Deng B; Park JH; Ren L; Yew PY; Kiyotani K; Antic T; O'Connor K; O'Donnell PH; Nakamura Y
Cancer Rep (Hoboken); 2018 Jun; 1(1):e1002. PubMed ID: 32729250
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 Checkpoint Inhibition Narrows the Antigen-Specific T Cell Receptor Repertoire in Chronic Lymphocytic Choriomeningitis Virus Infection.
Klein S; Ghersi D; Manns MP; Prinz I; Cornberg M; Kraft ARM
J Virol; 2020 Aug; 94(18):. PubMed ID: 32641478
[TBL] [Abstract][Full Text] [Related]
20.
Chen Y; Huang Y; Gao X; Li Y; Lin J; Chen L; Chang L; Chen G; Guan Y; Pan LK; Xia X; Guo Z; Pan J; Xu Y; Yi X; Chen C
Front Immunol; 2020; 11():1620. PubMed ID: 32903763
[No Abstract] [Full Text] [Related]
[Next] [New Search]
